Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Biotechnology

Healthcare
$20.58 -3.08%

-$0.74 today

Market cap
$302.08M
Beta
1.38
P/E (TTM)
-15.6
EPS (TTM)
-$1.49
52W Low $7.78High $34.10

Volume 0.71M

Average 0.14M

GLSI Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Greenwich LifeSciences, Inc.NASDAQ: GLSI

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns positive

Q1 FY2026 gross profit was $0, compared with -$903 a year earlier. Trailing-twelve-month gross profit was -$876.

Context

  • Gross profit grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$219.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
-$1.78K+50.7% YoY
LTMMar 2026
-$876+75.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+50.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(1.78K) USD
Year-over-year change
+50.7%

Gross Profit vs competitors

How GLSI compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +75.7% is the 2nd highest of 7, against a peer median of +43.9%.
GLSI Competitors
Gross Profit for GLSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$64.58M USD+289.3%—52.1%
SRZNSurrozen, Inc.LTM Mar 2026$7.43M USD-34.0%-31.7%99.1%
SEERSeer, Inc.LTM Mar 2026$7.26M USD+61.1%+70.5%48.3%
IRDOpus Genetics, Inc.LTM Mar 2026$5.95M USD+1.3%-29.1%49.6%
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026-$876 USD+75.7%——
HURATuHURA Biosciences, Inc.LTM Mar 2026-$23.47K USD+63.1%——
ONCYOncolytics Biotech Inc.LTM Mar 2026-CA$119.31K CAD+26.6%——
CGTXCognition Therapeutics, Inc.LTM Mar 2026-$129K USD———
IMMXImmix Biopharma, Inc.LTM Mar 2026-$130.77K USD———
Peer median (excluding GLSI) —+43.9%-29.1%50.9%

Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue3.61K3.61K3.61K3.61K1.78K
Gross Profit(3.61K)(3.61K)(3.61K)(3.61K)(1.78K)
Gross Margin—————
Research & Development3.56M6.48M7.7M15.48M17.22M
Selling, General & Admin1.04M1.56M1.63M2.15M2.23M
Operating Expenses4.59M8.04M9.32M17.63M19.45M
Depreciation & Amortization3.61K3.61K3.61K3.61K1.78K
EBITDA(4.57M)(7.82M)(8.89M)(17.41M)(19.36M)
EBITDA Margin—————
Operating Income(4.6M)(8.04M)(9.33M)(17.64M)(19.45M)
Operating Margin—————
Interest Income27.37K215.02K436.06K223.01K89.7K
Interest Expense00000
Other Income / Expenses27.37K215.02K436.06K223.01K89.7K
Income Before Tax(4.57M)(7.83M)(8.89M)(17.41M)(19.36M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(4.57M)(7.83M)(8.89M)(17.41M)(19.36M)
Net Margin—————
EPS (Basic)(0.35)(0.61)(0.69)(1.21)(1.43)
EPS (Diluted)(0.35)(0.61)(0.69)(1.21)(1.43)
Weighted Avg Shares12.94M12.91M12.85M13.01M13.53M
Weighted Avg Shares (Diluted)12.94M12.91M12.85M13.01M13.53M

Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Intrinsic Alpha fair value

Locked

Current Price

$20.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.